<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02527902</url>
  </required_header>
  <id_info>
    <org_study_id>1008123</org_study_id>
    <nct_id>NCT02527902</nct_id>
  </id_info>
  <brief_title>Autonomic Nervous System (ANS) and Renal Function in Immunoglobin A (IgA) Nephropathy</brief_title>
  <official_title>Autonomic Nervous System (ANS) Analysis According to Different Renal Function Stage in Immunoglobin A (IgA) Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The estimation of the cardiovascular risk in the general population must take into account
      small renal disturbances, as the microalbuminuria. Conversely certain parameters of the
      cardiovascular risk influence the evolution of renal diseases, for example the arterial high
      blood pressure.

      The measure of the activity of the autonomous nervous system, and especially the
      quantification of its variability, is a means to estimate the cardiovascular risk. The
      investigators formulate the hypothesis that the variability of the autonomous nervous system
      is an additional clinical element for the evaluation of the evolutionary risk of renal
      diseases.

      The aim of this study is to compare the variability of the autonomous nervous system during
      the various evolutionary stages of the renal disease.

      The renal disease studied will be IgA nephropathy (IgNA). IgNA is a histologically defined
      glomerulonephritis (rela biopsy) by the presence of deposits immunoglobulin A (IgA) in the
      renal mesangium (at list 1+) by immunofluorescence.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standard deviation of all R-R intervals (SDNN)</measure>
    <time_frame>day 1</time_frame>
    <description>Comparison of Standard deviation of all R-R intervals (SDNN) between GFR category of IgNA</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>IGA Glomerulonephritis</condition>
  <arm_group>
    <arm_group_label>IgAN with glomerular filtration rate (GFR) &gt;90 ml/min/1.73 m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measure of ANS by holter device in IgAN patients with glomerular filtration rate (GFR) &gt;90 ml/min/1.73 m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IgAN with GFR 60-89 ml/min/1.73 m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measure of ANS by holter device in IgAN patients with GFR 60-89 ml/min/1.73 m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IgAN with GFR 30-59 ml/min/1.73 m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measure of ANS by holter device in IgAN patients with GFR 30-59 ml/min/1.73 m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IgAN with GFR 15-29 ml/min/1.73 m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measure of ANS by holter device in IgAN patients with GFR 15-29 ml/min/1.73 m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IgAN with GFR &lt; 15ml/min/1.73 m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measure of ANS by holter device in IgAN patients with GFR &lt; 15ml/min/1.73 m2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Holter</intervention_name>
    <description>measure of ANS in IgAN patients</description>
    <arm_group_label>IgAN with glomerular filtration rate (GFR) &gt;90 ml/min/1.73 m2</arm_group_label>
    <arm_group_label>IgAN with GFR 60-89 ml/min/1.73 m2</arm_group_label>
    <arm_group_label>IgAN with GFR 30-59 ml/min/1.73 m2</arm_group_label>
    <arm_group_label>IgAN with GFR 15-29 ml/min/1.73 m2</arm_group_label>
    <arm_group_label>IgAN with GFR &lt; 15ml/min/1.73 m2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of IgNA biopsy-proven free, informed, express and written

        Exclusion Criteria:

          -  IgNA secondary to Henoch-Schonlein purpura (HSP) or Systemic Lupus Erythematosus or
             alcoholic cirrhosis

          -  current kidney transplantation

          -  Hypertension treated or not,

          -  Diseases interfering with ANS analysis: cardiac arrhythmia, beta-blocker therapy

          -  diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Alamartine, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Saint-Etienne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IGA Glomerulonephritis</keyword>
  <keyword>Autonomic nervous system</keyword>
  <keyword>ANS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

